The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
HIV Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
The human immunodeficiency virus (HIV) refers to a type of retrovirus that causes acquired immunodeficiency syndrome (AIDS). HIV attacks some immune cells and causes weakness of immune system resulting in loss of ability to fight against the organism that causes disease.
The global HIV Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of HIV Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Labs,, are propelling HIV Therapeutics market. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for HIV Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global HIV Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global HIV Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, HIV Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of HIV Therapeutics covered in this report include Boehringer Ingelheim International GmbH, Merck & Co., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, Gilead Sciences and Johnson & Johnson, etc.
The global HIV Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Boehringer Ingelheim International GmbH
Merck & Co.
ViiV Healthcare
AbbVie
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb
Gilead Sciences
Johnson & Johnson
Cipla Limited
Global HIV Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global HIV Therapeutics market, Segment by Type:
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
Global HIV Therapeutics market, by Application
Hospitals
Clinics
Labs
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of HIV Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The human immunodeficiency virus (HIV) refers to a type of retrovirus that causes acquired immunodeficiency syndrome (AIDS). HIV attacks some immune cells and causes weakness of immune system resulting in loss of ability to fight against the organism that causes disease.
The global HIV Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of HIV Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Labs,, are propelling HIV Therapeutics market. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for HIV Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global HIV Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global HIV Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, HIV Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of HIV Therapeutics covered in this report include Boehringer Ingelheim International GmbH, Merck & Co., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, Gilead Sciences and Johnson & Johnson, etc.
The global HIV Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Boehringer Ingelheim International GmbH
Merck & Co.
ViiV Healthcare
AbbVie
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb
Gilead Sciences
Johnson & Johnson
Cipla Limited
Global HIV Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global HIV Therapeutics market, Segment by Type:
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
Global HIV Therapeutics market, by Application
Hospitals
Clinics
Labs
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of HIV Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of HIV Therapeutics
1.1 HIV Therapeutics Market Overview
1.1.1 HIV Therapeutics Product Scope
1.1.2 HIV Therapeutics Market Status and Outlook
1.2 Global HIV Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global HIV Therapeutics Market Size by Region (2018-2029)
1.4 Global HIV Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global HIV Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, HIV Therapeutics Market Size (2018-2029)
1.6.1 North America HIV Therapeutics Market Size (2018-2029)
1.6.2 Europe HIV Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific HIV Therapeutics Market Size (2018-2029)
1.6.4 Latin America HIV Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa HIV Therapeutics Market Size (2018-2029)
2 HIV Therapeutics Market by Type
2.1 Introduction
2.1.1 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
2.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
2.1.3 Entry and Fusion Inhibitors
2.1.4 Protease Inhibitors (PIs)
2.1.5 Integrase Inhibitors
2.1.6 Coreceptor Antagonists
2.2 Global HIV Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global HIV Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global HIV Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America HIV Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe HIV Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific HIV Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America HIV Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa HIV Therapeutics Revenue Breakdown by Type (2018-2029)
3 HIV Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Labs
3.2 Global HIV Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global HIV Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global HIV Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America HIV Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe HIV Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific HIV Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America HIV Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa HIV Therapeutics Revenue Breakdown by Application (2018-2029)
4 HIV Therapeutics Competition Analysis by Players
4.1 Global HIV Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in HIV Therapeutics as of 2022)
4.3 Date of Key Players Enter into HIV Therapeutics Market
4.4 Global Top Players HIV Therapeutics Headquarters and Area Served
4.5 Key Players HIV Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 HIV Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Boehringer Ingelheim International GmbH
5.1.1 Boehringer Ingelheim International GmbH Profile
5.1.2 Boehringer Ingelheim International GmbH Main Business
5.1.3 Boehringer Ingelheim International GmbH HIV Therapeutics Products, Services and Solutions
5.1.4 Boehringer Ingelheim International GmbH HIV Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Boehringer Ingelheim International GmbH Recent Developments
5.2 Merck & Co.
5.2.1 Merck & Co. Profile
5.2.2 Merck & Co. Main Business
5.2.3 Merck & Co. HIV Therapeutics Products, Services and Solutions
5.2.4 Merck & Co. HIV Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Merck & Co. Recent Developments
5.3 ViiV Healthcare
5.3.1 ViiV Healthcare Profile
5.3.2 ViiV Healthcare Main Business
5.3.3 ViiV Healthcare HIV Therapeutics Products, Services and Solutions
5.3.4 ViiV Healthcare HIV Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 AbbVie Recent Developments
5.4 AbbVie
5.4.1 AbbVie Profile
5.4.2 AbbVie Main Business
5.4.3 AbbVie HIV Therapeutics Products, Services and Solutions
5.4.4 AbbVie HIV Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 AbbVie Recent Developments
5.5 F. Hoffmann-La Roche Ltd.
5.5.1 F. Hoffmann-La Roche Ltd. Profile
5.5.2 F. Hoffmann-La Roche Ltd. Main Business
5.5.3 F. Hoffmann-La Roche Ltd. HIV Therapeutics Products, Services and Solutions
5.5.4 F. Hoffmann-La Roche Ltd. HIV Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
5.6 Teva Pharmaceutical Industries Ltd.
5.6.1 Teva Pharmaceutical Industries Ltd. Profile
5.6.2 Teva Pharmaceutical Industries Ltd. Main Business
5.6.3 Teva Pharmaceutical Industries Ltd. HIV Therapeutics Products, Services and Solutions
5.6.4 Teva Pharmaceutical Industries Ltd. HIV Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Teva Pharmaceutical Industries Ltd. Recent Developments
5.7 Bristol-Myers Squibb
5.7.1 Bristol-Myers Squibb Profile
5.7.2 Bristol-Myers Squibb Main Business
5.7.3 Bristol-Myers Squibb HIV Therapeutics Products, Services and Solutions
5.7.4 Bristol-Myers Squibb HIV Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Bristol-Myers Squibb Recent Developments
5.8 Gilead Sciences
5.8.1 Gilead Sciences Profile
5.8.2 Gilead Sciences Main Business
5.8.3 Gilead Sciences HIV Therapeutics Products, Services and Solutions
5.8.4 Gilead Sciences HIV Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Gilead Sciences Recent Developments
5.9 Johnson & Johnson
5.9.1 Johnson & Johnson Profile
5.9.2 Johnson & Johnson Main Business
5.9.3 Johnson & Johnson HIV Therapeutics Products, Services and Solutions
5.9.4 Johnson & Johnson HIV Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Johnson & Johnson Recent Developments
5.10 Cipla Limited
5.10.1 Cipla Limited Profile
5.10.2 Cipla Limited Main Business
5.10.3 Cipla Limited HIV Therapeutics Products, Services and Solutions
5.10.4 Cipla Limited HIV Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Cipla Limited Recent Developments
6 North America
6.1 North America HIV Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe HIV Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific HIV Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America HIV Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa HIV Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 HIV Therapeutics Market Dynamics
11.1 HIV Therapeutics Industry Trends
11.2 HIV Therapeutics Market Drivers
11.3 HIV Therapeutics Market Challenges
11.4 HIV Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
